Logo Image

Jacob Sands, MD
Jacob Sands, MD

Jacob Sands, MD, is associate chief of the Lowe Center for Thoracic Oncology and oncology medical director of the International Patient Center at Dana-Farber Cancer Institute; as well as an assistant professor at Harvard Medical School

Articles by Jacob Sands, MD

Experts featured in this series.

NCCN Guidelines in ES-SCLC, Eligibility Criteria, and Communicating Survival Benefit

ByJoshua K. Sabari, MD,Anne Chiang, MD,Ticiana A. Leal, MD,Jacob Sands, MD,Misty D. Shields, MD, PhD
Published: | Updated:

Dr. Shields confirms that NCCN guidelines now recommend lurbinectedin plus atezolizumab as preferred maintenance therapy following 4 cycles of chemotherapy and immunotherapy, with the specific footnote limiting this to patients with ECOG performance status 0 to 1 and no history of brain metastases. She strictly follows the brain metastasis exclusion criteria for treatment-naive patients but notes this restriction wasn't applied in second or third-line relapse settings.

Experts featured in this series.

IMforte Trial Results and Efficacy Data

ByJoshua K. Sabari, MD,Anne Chiang, MD,Ticiana A. Leal, MD,Jacob Sands, MD,Misty D. Shields, MD, PhD
Published: | Updated:

Dr. Joshua Sabari introduces the program on evolving maintenance and sequencing strategies in extensive-stage small cell lung cancer (ES-SCLC), joined by Dr. Anne Chiang from Yale, Dr. Jacob Sands from Dana-Farber, Dr. Misty Shields from Indiana University, and Dr. Ticiana Leal from Emory University's Winship Cancer Institute.

EGFR-Mutated NSCLC: Emerging Role of TROP2-Directed Antibody–Drug Conjugates

ByJacob Sands, MD,Heather Wakelee, MD,Alissa J. Cooper, MD

In this segment, Dr. Sands asks Dr. Cooper to discuss the evolving role of TROP2-directed antibody–drug conjugates in EGFR-mutated non-small cell lung cancer. Dr. Cooper explains that these agents are designed to deliver cytotoxic payloads directly to tumor cells by targeting TROP2, a surface antigen expressed in many epithelial cancers, thereby enhancing antitumor activity while attempting to limit off-target effects.

EGFR-Mutated NSCLC: Interpreting Efficacy Outcomes in First-Line Therapy

ByJacob Sands, MD,Heather Wakelee, MD,Alissa J. Cooper, MD

In this segment, Dr. Sands invites Dr. Cooper to explain how she evaluates key efficacy outcomes in selecting first-line therapy for EGFR-mutated non-small cell lung cancer, emphasizing the importance of integrating progression-free survival, overall survival, CNS activity, and patient-specific factors to guide individualized, real-world treatment decisions.

EGFR-Mutated NSCLC: Evolving First-Line Treatment Landscape

ByJacob Sands, MD,Heather Wakelee, MD,Alissa J. Cooper, MD

In this opening segment, Dr. Sands invites the panel to outline the current treatment landscape for EGFR-mutated non-small cell lung cancer, with Dr. Wakelee and Dr. Cooper highlighting how recent advances, including data from key phase III trials, are shaping first-line decisions, balancing monotherapy and combination strategies, and integrating efficacy, CNS activity, and tolerability into real-world clinical practice.

Latest Updated Articles